This trial is testing a new immunotherapy treatment for patients with multiple myeloma that has come back or does not respond to treatment. The treatment consists of two drugs given with dexamethasone, a chemotherapy drug. The trial will test how well the treatment works.
- Multiple Myeloma
1 Primary · 0 Secondary · Reporting Duration: From the date of first dose of any study drug treatment to the date of first documentation of progressive disease, or death due to any cause, whichever occurs first, assessed up to 18 months
Awards & Highlights
1 Treatment Group
Treatment (daratumumab, bortezomib, dexamethasone, ixazomib)
1 of 1
60 Total Participants · 1 Treatment Group
Primary Treatment: Daratumumab · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 1 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What health issues is Quality-of-Life Assessment typically utilized to address?
"Quality-of-Life Assessment can be employed to manage ophthalmia, sympathetic issues, branch retinal vein occlusions, and macular edema." - Anonymous Online Contributor
What is the upper limit of participants involved in this research?
"Affirmative. Information posted on clinicaltrials.gov reveals that this experiment is actively seeking participants, having been initially published on January 17th 2019 and recently revised October 12th 2022. The research project needs 60 volunteers from one single site to complete its objectives." - Anonymous Online Contributor
Has Quality-of-Life Assessment been studied as part of other medical experiments?
"Currently, there are 666 total studies dedicated to Quality-of-Life Assessment. Of those trials, 153 have entered Phase 3 and 21947 locations are hosting them. Joliet, Illinois is the main hub for these investigations." - Anonymous Online Contributor
Are there any open recruitment opportunities to participate in this trial?
"Verified. According to the details posted on clinicaltrials.gov, this trial is seeking participants and was initially published in January of 2019 with its most recent update occurring in October 2022." - Anonymous Online Contributor
What risks should be considered when evaluating Quality-of-Life Assessment?
"Due to the Phase 2 trial for Quality-of-Life Assessment, our team at Power evaluated its safety with a score of 2. This is because there exists some data that suggests it may be safe but no evidence supporting efficacy yet." - Anonymous Online Contributor